ORUM Cash Flow Conversion Efficiency
ORUM cash flow conversion efficiency. Based on the latest financial reports, ORUM (475830) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-15.34 Billion ≈ $-10.39 Million USD) by net assets (₩119.57 Billion ≈ $81.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ORUM (2022–2025)
Cash flow conversion efficiency of ORUM from 2022 to 2025. This chart illustrates how ORUM's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ORUM share price for real-time trading data and today's change.
ORUM Cash Flow Conversion Ratio Explained
ORUM cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ORUM Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORUM ranked by their cash flow conversion efficiency. Also see 475830 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sakar Healthcare Limited
NSE:SAKAR
|
0.094x |
|
Korea No. 9 Special Purpose Acquisition Co. Ltd.
KQ:368770
|
0.092x |
|
CM.com NV
AS:CMCOM
|
-0.149x |
|
Federal Corp
TW:2102
|
-0.009x |
|
Amazing Microelectronic
TWO:6411
|
0.027x |
|
GBank Financial Holdings Inc. Common Stock
NASDAQ:GBFH
|
-0.058x |
|
Pact Group Holdings Ltd
AU:PGH
|
0.035x |
|
HengFeng Information Technology Co Ltd
SHE:300605
|
0.084x |
Annual Cash Flow Conversion Efficiency for ORUM (2022–2025)
The table below shows the annual cash flow conversion efficiency of ORUM from 2022 to 2025. Review 475830 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩130.89 Billion ≈ $88.70 Million |
₩-35.99 Billion ≈ $-24.39 Million |
-0.275x | -196.77% |
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
₩-11.28 Billion ≈ $-7.65 Million |
-0.093x | +94.48% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
₩94.24 Billion ≈ $63.87 Million |
-1.678x | -620.35% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
₩-41.09 Billion ≈ $-27.85 Million |
0.322x | -- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more